Compare EXPD & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXPD | NBIX |
|---|---|---|
| Founded | 1979 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.3B | 14.4B |
| IPO Year | N/A | 1996 |
| Metric | EXPD | NBIX |
|---|---|---|
| Price | $151.33 | $155.51 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 19 |
| Target Price | $129.22 | ★ $173.79 |
| AVG Volume (30 Days) | ★ 1.5M | 969.9K |
| Earning Date | 11-04-2025 | 10-28-2025 |
| Dividend Yield | ★ 1.02% | N/A |
| EPS Growth | ★ 20.10 | 12.44 |
| EPS | ★ 6.15 | 4.19 |
| Revenue | ★ $11,167,760,000.00 | $2,682,700,000.00 |
| Revenue This Year | $3.06 | $23.76 |
| Revenue Next Year | N/A | $18.01 |
| P/E Ratio | ★ $24.64 | $37.10 |
| Revenue Growth | 12.54 | ★ 19.61 |
| 52 Week Low | $100.47 | $84.23 |
| 52 Week High | $151.67 | $157.67 |
| Indicator | EXPD | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 75.95 | 64.81 |
| Support Level | $144.93 | $150.26 |
| Resistance Level | $147.87 | $154.35 |
| Average True Range (ATR) | 2.89 | 4.16 |
| MACD | 0.18 | 1.07 |
| Stochastic Oscillator | 98.14 | 93.25 |
Based in the US, Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. Its offers freight consolidation and forwarding, customs brokerage, warehousing and distribution, purchase order management, vendor consolidation, and numerous other value-added logistics services. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. Expeditors derives around 35% of consolidated gross revenue from airfreight, 30% from ocean freight, and 36% from customs brokerage and other services.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.